New vaccine shows promise against Hard-to-Treat cancers
⭐️ VACCINE ⭐️
Ongoing
This trial tests a new genetic vaccine called Nous-209, combined with the drug pembrolizumab, in adults with specific types of cancer that have a genetic flaw called MSI-H or dMMR. The cancers studied include colorectal, stomach, and gastro-esophageal junction tumors that cannot …
Phase: PHASE1, PHASE2 • Sponsor: Nouscom SRL • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:53 UTC